ArticleFrontiers in psychiatry2025
Bee venom-derived phospholipase A
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bee venom phospholipase A2 (bvPLA2) exhibits therapeutic potential in inflammatory disorders through the modulation of microglial activation, a mechanism implicated in the pathogenesis of depression. However, its effects in the context of menopausal depression remain uncharacterized. This study investigated the antidepressant effects of bvPLA2 and its underlying mechanisms in an ovariectomized (OVX) mouse model subjected to chronic restraint stress. Method: Female C57BL/6 mice were assigned to six groups: Nor (normal), Sham (the operated-only abdominal incision and non-stressed group), OVX (ovariectomized with stress), PC (positive control; estradiol-treated), bvPLA2-0.2 (0.2 mg/kg), and bvPLA2-1 (1 mg/kg). Restraint stress (2 h/day) was applied for 14 consecutive days. bvPLA2 was administered intraperitoneally, and estradiol was administered subcutaneously, once daily for two weeks. Behavioral assessments included the tail suspension test (TST), open field test (OFT), and elevated plus maze (EPM). Serum levels of corticosterone (CORT), estradiol, interleukin-1β (IL-1β), superoxide dismutase (SOD), and glutathione (GSH) were quantified via ELISA. Immunohistochemical and immunofluorescence analyses were conducted to evaluate microglial activation (CD11b), c-Fos expression, and M1/M2 polarization (CD86, CD206), with a focus on the paraventricular nucleus (PVN) of the hypothalamus. Results: bvPLA2 significantly reduced immobility time in the TST and enhanced exploratory behavior in the OFT and EPM relative to the OVX group. Treatment also lowered serum CORT and IL-1β levels and increased estradiol, SOD, and GSH concentrations, with more pronounced effects at 1 mg/kg. Furthermore, bvPLA2 attenuated microglial M1 polarization and promoted M2 polarization, suggesting suppression of neuroinflammatory responses. Discussion: These results indicate that bvPLA2 exerts antidepressant-like effects in OVX-induced menopausal depression, potentially through the modulation of neuroinflammation and oxidative stress pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.